There is something about the recent price action that should make more people stop and think.
The stock drops around 12% in a single day on roughly five times normal volume. In the week leading up, expectations across Reddit were that the price would move toward 10 once the data was released. Instead, we are now looking at ~7.5, and the dominant explanations are either “sell the news” or manipulation by larger players.
That is possible. But it is also a very convenient explanation. Especially given that a large part of DRTS’ shareholder base consists of retail investors. When the market reacts negatively, it is at least worth considering whether the reaction is driven by the data itself.
I am writing this as someone who has held the stock for several years and still has a significant position. That is exactly why it is concerning to see how one-sided the discussion has become, particularly on Reddit. The same positive talking points are repeated, while risks and weaknesses are barely mentioned. After the latest data, that tendency has only intensified, almost as if the conclusion was decided in advance. That is rarely a healthy sign.
Looking at the data more objectively:
Population and data quality: only 19 evaluable patients, pooled from two studies, with a highly heterogeneous population including patients ineligible for chemotherapy and others who had received up to four prior lines of treatment. There is no control group, no clear comparability, and no well-defined follow-up period. We do not know how durable the effect is, how patients are doing over time, or how many are still alive. “Tumor shrinkage” sounds encouraging, but without context—duration, patient selection, and natural disease variation—it is difficult to interpret.
Response rate in context: reported outcomes are 21% partial response, 79% stable disease, and 100% disease control. On Reddit this is often framed as very strong. In reality, a ~21% response rate is lower than or at best in line with existing chemotherapy regimens. FOLFIRINOX typically shows ~25–35%, and gemcitabine plus nab-paclitaxel ~20–25%, both based on large, controlled trials. Here we are looking at 19 patients with no control arm.
Survival, which ultimately matters most: pancreatic cancer remains highly lethal. With current standard treatments, median overall survival is roughly 8–11 months, around 20–30% of patients are alive at one year, and fewer than 5–10% at five years. For the current dataset, there are no clear survival data and no evidence yet of prolonged life. At this stage, there is simply no basis to conclude that this treatment meaningfully changes mortality. That stands in contrast to some of the more enthusiastic claims on Reddit suggesting that this approach “saves patients.” There is no evidence for that yet.
What could it be? The most realistic interpretation at this point is a potential local treatment modality, possibly relevant for patients who cannot tolerate chemotherapy or as part of combination strategies. But there is still a long way from these early signals to broad clinical adoption.
ASCO perspective: if these data were as strong and practice-changing as some suggest, they would be presented on the main stage at ASCO. They are not. The company has an oral presentation, but not a plenary slot where truly practice-changing studies are showcased. That does not make the data worthless, but it does indicate that they are still considered early and not yet standard-changing.
Conclusion: the data are interesting but very early. The response rate is not superior to existing treatments and is based on a far weaker evidence base. Survival impact is unknown. The recent price decline may simply reflect that expectations were higher than what the data could support. The more concerning issue is not the data themselves, but the lack of balance in the discussion, particularly on Reddit. Any long-term investor should be able to hold two thoughts at once: the potential and the uncertainty. Right now, the former is dominating almost completely.